Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630015 · ClinicalTrials.gov registry record
Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 134
- Enrollment target
NCT04630015: Completed study, sponsored by University of California, San Francisco.
NCT04630015 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04630015 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic. This study may help to evaluate the impact of the survivorship program on patient well-being, provide evidence for use in grant application and publications, and ultimately inform the continued improvement of survivorship care.
Primary Outcome
The PROMIS Anxiety Short form consists of 2 items addressing patient anxiety with item response scores ranging from 1 (never) to 5 (Always). Raw scores are converted to scaled T-scores with higher scores indicating a greater level of anxiety. Significant changes over time and trends in patient reported outcomes will be analyzed via student's T-test.
Interventions
- OTHER Survey Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2023-05-01 |
What the finished NCT04630015 record still lists
NCT04630015 is an observational study that tracks outcomes without assigning an intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Survey Administration is the first listed.
NCT04630015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04630015 about?
NCT04630015 is a clinical study titled "Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth". This study evaluates the effects of the Survivorship Wellness Group Program following active treatment, as well as to learn from Survivorship Wellness participants about their concerns regarding the current COVID-19 pandemic. This study may help to evaluate the impact of the survivorship program on ...
What is the current status of trial NCT04630015?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2020-08-31. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT04630015?
The interventions under investigation include: Survey Administration (OTHER).
Who is sponsoring clinical trial NCT04630015?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI